Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Convertible Debt: 2020-2023

  • Mereo BioPharma Group's Convertible Debt was N/A to $4.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Mereo BioPharma Group reported Convertible Debt of $4.4 million as of Q4 2023, which was down 78.13% from $20.1 million recorded in Q2 2022.
  • In the past 5 years, Mereo BioPharma Group's Convertible Debt ranged from a high of $21.3 million in Q4 2020 and a low of -$2.5 million during Q2 2021.
  • In the last 3 years, Mereo BioPharma Group's Convertible Debt had a median value of $11.9 million in 2021 and averaged $10.3 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Convertible Debt declined by 9.03% in 2021 and then surged by 902.03% in 2022.
  • Quarterly analysis of 4 years shows Mereo BioPharma Group's Convertible Debt stood at $21.3 million in 2020, then decreased by 9.03% to $19.4 million in 2021, then surged by 902.03% to $20.1 million in 2022, then reached $4.4 million in 2023.
  • Its Convertible Debt was $4.4 million in Q4 2023, compared to $20.1 million in Q2 2022 and $19.4 million in Q4 2021.